Last reviewed · How we verify
NCT06874907: GLUCO-GCM
First Trimester Prediction of Gestational Diabetes Mellitus by Continuous Glucose Monitoring.
trial testing Glucose monitoring in Gestational Diabetes Mellitus in Pregnancy in 1,000 participants. Currently enrolling.
1 March 2026
Quick facts
| Lead sponsor | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 March 2025 |
| Primary completion | 1 March 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Glucose monitoring
Conditions studied
- Gestational Diabetes Mellitus in Pregnancy — all drugs for Gestational Diabetes Mellitus in Pregnancy →
Sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia — full company profile →
Who can join
18 and older, female only, with Gestational Diabetes Mellitus in Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Gestational diabetes mellitus (GDM) is the most common complication of pregnancy, with an incidence rate of 10-15% \[1\]. Common risk factors for GDM are increased maternal age and weight and as a consequence of women delaying childbirth and increasing incidence of obesity, there is a corresponding increase in the rate of GDM. GDM is associated with an increased risk of maternal and perinatal short and long-term complications . These include macrosomia, shoulder dystocia, neonatal hypoglycaemia, neonatal hyperbilirubinemia, and perinatal mortality. Maternal complications include higher risks of hypertensive disorders, perineal trauma, and caesarean section. Additionally, both the mothers with GDM and their infants have an increased risk of developing type 2 diabetes mellitus and cardiovascular disease later in life . Screening and diagnosis of GDM is currently based on an oral glucose tolerance (OGTT), which is carried out at 26-28 weeks' gestation. In addition, an OGTT is carried out at 11-13 weeks in women considered to be at increased risk of GDM based on their demographic characteristics and medical history. Screening and diagnosis of GDM is traditionally delayed until the late second or early third trimester of pregnancy with the rationale that the diabetogenic effects of pregnancy increase with gestation and therefore delayed testing would maximize the detection rate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06874907
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Glucose monitoring
Trials testing the same drug.
- NCT04225455 — The Use of the Dexcom G6® in Commercial Pilots With Insulin-treated Diabetes · active not recruiting
- NCT03819725 — Monitoring of Postprandial Glycemic Variability in Healthy Young Infants · NA · completed
Other recruiting trials for Gestational Diabetes Mellitus in Pregnancy
Currently open trials in the same condition.
- NCT05388643 — Early Detection of Gestational Diabetes Mellitus in Pregnancy · NA · recruiting
- NCT06957028 — CGM for the Early Detection and Management of Hyperglycemia in Pregnancy · NA · recruiting
- NCT06802861 — Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclam · recruiting
- NCT06548828 — Effects of a Non-nutritive Sweetener Reduction Intervention in Pregnancy and Lactation on Maternal and Infant Outcomes · NA · recruiting
- NCT06005987 — Mobile App Logging for Diabetes in Pregnancy · NA · recruiting
Other Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia trials
Trials by the same sponsor.
- NCT07064811 — Standardized Resistance Training Program and Assessment System for Prostate Cancer Patients Receiving Androgen Deprivati · NA · not yet recruiting
- NCT06646562 — Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months. · Phase 4 · recruiting
- NCT06858345 — Study of Maternal and Fetal Cardiovascular Function in Hypertensive States of Pregnancy · recruiting
- NCT06713486 — Efficacy of Self-titration of Ventilation in Overlap Syndrome (chronic Obstructive Pulmonar Disease + Sleep Apnea Syndro · NA · not yet recruiting
- NCT06449430 — Use of Propofol as a Sedative Agent Versus Spinal Analgesia With Bupivacaine in External Cephalic Version · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06874907 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06874907.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing